Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.-论文-万方医学网

作者： Raphael J,Landovitz ^[1] ; Sue,Li ^[2] ; Beatriz,Grinsztejn ^[3] ; Halima,Dawood ^[4] ; Albert Y,Liu ^[5] ; Manya,Magnus ^[6] ; Mina C,Hosseinipour ^[7] ; Ravindre,Panchia ^[8] ; Leslie,Cottle ^[2] ; Gordon,Chau ^[2] ; Paul,Richardson ^[9] ; Mark A,Marzinke ^[9] ; Craig W,Hendrix ^[9] ; Susan H,Eshleman ^[9] ; Yinfeng,Zhang ^[9] ; Elizabeth,Tolley ^[10] ; Jeremy,Sugarman ^[9] ; Ryan,Kofron ^[11] ; Adeola,Adeyeye ^[1] ; David,Burns ^[12] ; Alex R,Rinehart ^[12] ; David,Margolis ^[13] ; William R,Spreen ^[13] ; Myron S,Cohen ^[13] ; Marybeth,McCauley ^[14] ; Joseph J,Eron ^[10]

作者单位： UCLA Center for Clinical AIDS Research and Education, Los Angeles, California, United States of America. ^[1] Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center, Seattle, Washington, United States of America. ^[2] Evandro Chagas National Institute of Infectious Diseases, Oswaldo Cruz Foundation, Rio de Janeiro, Brazil. ^[3] Centre for the AIDS Programme of Research in South Africa, University of KwaZulu Natal, Durban, South Africa. ^[4] Bridge HIV, Population Health Division, San Francisco Department of Health, San Francisco, California, United States of America. ^[5] Department of Epidemiology and Biostatistics, Milken Institute School of Public Health, George Washington University, Washington, District of Columbia, United States of America. ^[6] UNC Project-Malawi, Lilongwe, Malawi. ^[7] Perinatal HIV Research Unit, Chris Hani Baragwanath Hospital, Soweto, South Africa. ^[8] School of Medicine, Johns Hopkins University, Baltimore, Maryland, United States of America. ^[9] FHI360, Durham, North Carolina, United States of America. ^[10] Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland, United States of America. ^[11] Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, United States of America. ^[12] ViiV Healthcare, Durham, North Carolina, United States of America. ^[13] University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America. ^[14]

主题词青少年(Adolescent);成年人(Adult);老年人(Aged);抗HIV药(Anti-HIV Agents);巴西(Brazil);迟效制剂(Delayed-Action Preparations);双盲法(Double-Blind Method);用药计划表(Drug Administration Schedule);药物监测(Drug Monitoring);女(雌)性(Female);HIV感染(HIV Infections);人类(Humans);注射, 肌肉内(Injections, Intramuscular);马拉维(Malawi);男(雄)性(Male);中年人(Middle Aged);吡啶酮类(Pyridones);危险性评估(Risk Assessment);危险因素(Risk Factors);南非(South Africa);治疗结果(Treatment Outcome);美国(United States);青年人(Young Adult)

DOI 10.1371/journal.pmed.1002690

PMID 30408115

发布时间 2023-10-04

检索历史清除

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

PLoS medicine

相似文献

PLoS medicine

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial.

PLoS medicine

相似文献

PLoS medicine

相关期刊

检索历史清除